Immune system response to a substance that most people tolerate well
POPULARITY
Categories
92 episodes with Allergy
98 episodes with Allergy
44 episodes with Allergy
37 episodes with Allergy
33 episodes with Allergy
59 episodes with Allergy
41 episodes with Allergy
45 episodes with Allergy
78 episodes with Allergy
79 episodes with Allergy
30 episodes with Allergy
31 episodes with Allergy
29 episodes with Allergy
50 episodes with Allergy
49 episodes with Allergy
20 episodes with Allergy
15 episodes with Allergy
16 episodes with Allergy
13 episodes with Allergy
12 episodes with Allergy
18 episodes with Allergy
11 episodes with Allergy
10 episodes with Allergy
32 episodes with Allergy
14 episodes with Allergy
16 episodes with Allergy
22 episodes with Allergy
14 episodes with Allergy
7 episodes with Allergy
17 episodes with Allergy
11 episodes with Allergy
14 episodes with Allergy
9 episodes with Allergy
11 episodes with Allergy
10 episodes with Allergy
27 episodes with Allergy
7 episodes with Allergy
12 episodes with Allergy
12 episodes with Allergy
205 episodes with Allergy
9 episodes with Allergy
10 episodes with Allergy
4 episodes with Allergy
9 episodes with Allergy
12 episodes with Allergy
7 episodes with Allergy
6 episodes with Allergy
6 episodes with Allergy
6 episodes with Allergy
25 episodes with Allergy
8 episodes with Allergy
5 episodes with Allergy
8 episodes with Allergy
5 episodes with Allergy
8 episodes with Allergy
7 episodes with Allergy
9 episodes with Allergy
8 episodes with Allergy
8 episodes with Allergy
7 episodes with Allergy
4 episodes with Allergy
5 episodes with Allergy
5 episodes with Allergy
5 episodes with Allergy
19 episodes with Allergy
7 episodes with Allergy
4 episodes with Allergy
6 episodes with Allergy
3 episodes with Allergy
16 episodes with Allergy
7 episodes with Allergy
8 episodes with Allergy
7 episodes with Allergy
11 episodes with Allergy
5 episodes with Allergy
5 episodes with Allergy
7 episodes with Allergy
12 episodes with Allergy
6 episodes with Allergy
5 episodes with Allergy
7 episodes with Allergy
4 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
3 episodes with Allergy
6 episodes with Allergy
7 episodes with Allergy
7 episodes with Allergy
15 episodes with Allergy
6 episodes with Allergy
14 episodes with Allergy
5 episodes with Allergy
4 episodes with Allergy
6 episodes with Allergy
10 episodes with Allergy
6 episodes with Allergy
9 episodes with Allergy
4 episodes with Allergy
4 episodes with Allergy
5 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
3 episodes with Allergy
4 episodes with Allergy
4 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
5 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
5 episodes with Allergy
3 episodes with Allergy
3 episodes with Allergy
3 episodes with Allergy
4 episodes with Allergy
6 episodes with Allergy
5 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
5 episodes with Allergy
8 episodes with Allergy
8 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
3 episodes with Allergy
2 episodes with Allergy
5 episodes with Allergy
6 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
5 episodes with Allergy
3 episodes with Allergy
7 episodes with Allergy
3 episodes with Allergy
4 episodes with Allergy
7 episodes with Allergy
4 episodes with Allergy
3 episodes with Allergy
77 episodes with Allergy
3 episodes with Allergy
5 episodes with Allergy
2 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
7 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
2 episodes with Allergy
4 episodes with Allergy
72 episodes with Allergy
As parents, we expect the occasional food reaction. Maybe a rash, some fussiness, or a tummy ache. But what happens when your child suddenly becomes violently ill hours after eating something they've had before, and no one seems to know why? That was my reality when Jasper had this kind of reaction to shrimp. Inside this episode, I'm digging into: What FPIES is and how it differs from IgE-mediated food allergies Common trigger foods and why reactions can show up hours later Our experience with Jasper's shrimp reaction (and what we learned from it) How to navigate fear around food after a reaction Why trusting your instincts and advocating for your child matters --- Show Notes: Sign up for a 1:1 Discovery Call Join the Imperfectly Paige Wellness Community Join the Compass Method DIY Program Jump inside my Rock the Bloat Minicourse Get my Core-Gi Workout Program with the exclusive listener discount! Join my Brain Rewiring Masterclass You can learn more about me by following on IG @imperfectlypaigewellness or by checking out my blog, freebies, and offers on my website: https://imperfectlypaigewellness.com Please share with #PaigeTalksWellness to help get the word out about the show - and join the Imperfect Health Fam over on Facebook.
When should an antibiotic allergy actually be tested? In this episode of the BackTable ENT Podcast, guest host Dr. Basil Kahwash, an allergist and immunologist at Ohio ENT & Allergy, sits down with Dr. Cosby Stone, an allergist and immunologist at Vanderbilt University Medical Center, to discuss antibiotic allergies and how to distinguish true allergies from intolerances. --- SYNPOSIS Dr. Stone breaks down common misconceptions around antibiotic allergies, with a focus on penicillin and cephalosporins. The conversation explores how these allergies are evaluated, including when skin testing is appropriate, why inaccurate allergy labels matter, and how confirmed allergies should be managed long term. They also dive into more advanced topics such as drug desensitization, current research in the field, and where the future of drug allergy evaluation is headed. --- TIMESTAMPS 00:00 - Introduction 01:03 - Understanding Antibiotic Allergies07:28 - The Importance of Accurate Allergy Diagnosis10:55 - Key Questions for Diagnosing Allergies17:10 - Implementing Allergy Testing in Healthcare Settings19:06 - Identifying Severe Allergic Reactions26:31 - Interpreting Allergy Skin Testing Procedures33:17 - Penicillin and Cephalosporin Cross-Reactivity37:15 - Drug Desensitization: Indications and Process40:30 - Prognosis and Long-Term Outcomes of Drug Allergies47:22 - Conclusion and Final Thoughts --- RESOURCES Dr. Basil Kahwash https://www.ohioentandallergy.com/physicians/basil-kahwash-md/ Dr. Cosby Stonehttps://www.vanderbilthealth.com/doctors/stone-cosby
How does a tick bite end up with you being allergic to meat? It might sound the stuff of science fiction, but there's a syndrome called 'alpha-gal syndrome' which can be traced back to being bitten by a certain type of tick. The allergy is more commonly called the 'Mammalian meat allergy', with those affected potentially ending up being allergic to meat.
Today, I'm joined by Dr. Maeve O'Connor, a board-certified allergist and immunologist practicing in Charlotte, North Carolina. Dr. O'Connor's training reflects both rigor and range. She completed dual undergraduate degrees at the University of South Carolina Honors College with a Bachelor of Science in Biology and a Bachelor of Arts in Spanish before earning her medical degree at the University of South Carolina School of Medicine. She then completed her internship and residency at the University of Texas and its affiliated hospitals in Houston, where she served as Chief Medical Resident. Her subspecialty training in Allergy and Immunology was completed at the National Jewish Medical and Research Center in Denver consistently ranked the number one respiratory hospital in the United States where she developed deep expertise in asthma, allergic disease, and immune dysregulation. She further expanded her clinical lens through fellowship training in Integrative Medicine at the University of Arizona from 2013 to 2015. Clinically, Dr. O'Connor works at the intersection of pediatrics, immunology, and real family life where eczema isn't just a rash, food reactions aren't just labels, and immune symptoms rarely fit neatly into algorithmic boxes. Her work emphasizes careful diagnosis, evidence-based treatment, and avoiding both over-medicalization and missed pathology. In a time when allergy medicine is often reduced to test results and avoidance lists, Dr. O'Connor brings a grounded, thoughtful approach helping families and clinicians distinguish what's truly allergic, what's inflammatory, what's developmental, and what's simply noise. Today, we'll explore how allergic disease actually presents in children, why mislabeling is so common, how early immune signals shape long-term health, and how pediatricians and specialists can collaborate more effectively without fear-based medicine. This is a conversation about immune literacy, clinical nuance, and doing better for children in a world where their immune systems are under increasing pressure. I'm excited to welcome Dr. Maeve O'Connor. Dr. M
From Food Allergy Parent to Published Author and CEO: Meenal Lele on Building an Evidence-Based Prevention Company as Delaware Mandates Insurance Coverage As Delaware implements the nation's first insurance mandate for early allergen introduction on January 1st, 2026, Meenal Lele, Founder & CEO of Lil Mixins and author of The Baby and the Biome, shares her journey from food allergy parent to medical entrepreneur. With multiple patents, published clinical studies, and an engineering background, Meenal built Hanimune Therapeutics to address a crisis affecting 33 million Americans. She discusses the clinical evidence behind early allergen introduction, navigating insurance coverage, and why state-level policy changes matter for reducing childhood allergies while saving healthcare systems millions. Discover how maternal insight combined with scientific rigor is transforming prevention. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/
Your gut's nervous system directly influences whether you tolerate foods or react to them, making it a key factor in food sensitivities and allergy risk A tiny nerve messenger called the vasoactive intestinal peptide (VIP) tells your gut stem cells how to rebuild the intestinal lining; when VIP drops, your gut produces too many tuft cells that trigger allergy like inflammation Everyday exposures — like microplastics, seed oils, and emulsifiers found in processed foods — damage tight junction proteins, weaken your gut barrier, and increase the flow of irritants into your bloodstream Low vitamin D, disrupted sleep, and high stress interfere with your gut's ability to maintain barrier integrity and calm immune activity, raising your vulnerability to allergic reactions You can lower your allergy risk by supporting mitochondrial function, removing gut damaging triggers, restoring healthy carbs in the right order, and improving the nerve-gut connection that regulates intestinal healing
Michael Berry continues his conversation with Dr. Chris Colosso about pollen, dust mites, allergy shots, and the science behind why spring hits so hard.See omnystudio.com/listener for privacy information.
== Happy holidays to our audience around the world! As a gift, and a break for The Allergist team, we are replaying our most popular episode from 2025. We hope you enjoy it as much this time around. See you in the New Year! ==“We have to keep in mind that urticaria has to be treated until it's completely gone. So, absolute control of the disease.” — Dr. Hermenio LimaChronic spontaneous urticaria has long been managed with the goal of complete symptom control. But for many patients, that goal remains elusive. In this episode of The Allergist, Dr. Mariam Hanna talks with dermatologist and clinical immunologist Dr. Hermenio Lima about the updated urticaria guidelines—and how new treatment options are giving clinicians more ways to act, and more hope for getting patients all the way to control.On this episode:What's new in the 2025 guideline—including additional second-line options beyond antihistaminesWhy nearly 40% of patients may need to escalate to biologicsHow remibrutinib compares to omalizumab and what its trials revealedWhat the CUPID studies say about dupilumab, especially in biologic-naive patientsKey safety signals and clinical considerations for the new treatment optionsHow to move toward full disease control—and why suboptimal outcomes are no longer acceptableComplete control is still the destination, but the path to get there is about to get a lot more flexible.Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions
Reading food labels can feel like a full-time job when you or your child has food allergies. Even when you know what to avoid, labels can still be confusing, especially when you run into “may contain” warnings. Marion Groetch, a registered dietitian with decades of experience in food allergy care and education, joins us to unpack all things food labels. Together, we break down U.S. allergen labeling laws, what parts of the package actually matter, and why “may contain” statements are a much grayer area than most people realize. We also share practical tips for navigating so-called “mystery ingredients” like natural flavors and oils, when it is worth contacting a manufacturer, and how to avoid being more restrictive than necessary while still staying safe. What we cover in our episode about food labels: What U.S. labeling laws require: How FALCPA and the FASTER Act protect families by requiring clear disclosure of the Top 9 major allergens. Where allergy information actually lives on a label: Why the ingredients list and “Contains” statement matter most, and why front-of-package claims should be ignored. What “may contain” actually means: Why these statements are voluntary and unregulated, and what that means for real-world decision-making. Foods that fall outside labeling laws: Common situations where allergen labeling is not required, including deli foods, restaurant meals, airline meals, and alcohol. How to avoid over-restricting your diet: Practical guidance on mystery ingredients, higher-risk products, and when contacting a manufacturer actually makes sense. ___ Made in partnership with The Allergy & Asthma Network. Thanks to Genentech for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
What is a call? How does a person know if God is calling them to mission service? Join in a discussion as these and other questions are addressed.
Covid-19 har på många sätt präglat våra liv under de senaste åren, och nya forskningsresultat fortsätter att ge oss insikt i hur immunförsvaret agerar i samband med viral infektion. Ett exempel på detta är den studie som Philip Curman, specialist i dermatologi vid Karolinska Universitetssjukhuset i Solna, disputerad inom genetiska hudsjukdomar och forskare inom dermatologisk epidemiologi vid Karolinska Institutet, nyligen publicerade i The Journal of Allergy and Clinical Immunology tillsammans med ett internationellt forskarlag.I studien, som baserades på den amerikanska elektroniska hälsodatabasen TriNetX, undersökte man sambandet mellan covid-19-infektion och typ 2-inflammatoriska sjukdomar, och fann en markant ökad risk för personer som haft covid-19 att utveckla astma, kronisk bihåleinflammation och/eller allergisk rinit. Däremot såg man ingen ökad risk för typ 2-inflammatoriska sjukdomar i huden, som atopisk dermatit, eller i matstrupen i form av eosinofil esofagit. En ännu tydligare skillnad framträdde vid jämförelse med individer som vaccinerats mot covid-19, vilket indikerar att vaccination inte bara skyddar mot infektion i sig, utan även verkar ha en viss förebyggande effekt mot vissa följdsjukdomar i luftvägarna. I detta avsnitt diskuterar han studiens upplägg och resultat, potentiella begränsningar och såväl planerade som pågående forskningsprojekt inom typ 2-inflammation, som förhoppningsvis kan bidra till ökad förståelse för immunaktivering och sjukdomsutveckling.Läs mer om den aktuella studien och pågående och kommande forskningsprojekt här:COVID-19 infection raises respiratory type 2 inflammatory disease risk, whereas vaccination is protective - ScienceDirectPhilip Curman | Karolinska Institutet
A complete look at asthma, including asthma pathophysiology, causes, as well as asthma signs and symptoms. Also includes how asthma is diagnosed as well as asthma treatment.PDFs available at: https://rhesusmedicine.com/pages/respiratoryConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Buy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Asthma / Asthma Definition0:22 Asthma Pathophysiology - Anatomy1:09 Asthma Molecular Pathology (Early v Late Phase) 3:12 Airway Remodelling3:40 Asthma Causes & Risk Factors4:40 Asthma Symptoms 5:38 Asthma Diagnosis (Chronic - Includes Spirometry)7:15 Acute Exacerbation of Asthma (Mnemonic)8:00 Asthma Treatment - Stepwise ApproachLINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesNational Center for Biotechnology Information (NCBI), 2018. Asthma. [online] Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157154/. PubMed CentralWiley Online Library, 2023. Allergic disease article. Allergy [online] Available at: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14607. (Exact article title assumed – if you want the full title, provide the page text).National Center for Biotechnology Information (NCBI), 2025. Pathophysiology of Asthma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [online] Available at: https://www.ncbi.nlm.nih.gov/books/NBK551579/. NCBIMoore, V.C., 2025. Spirometry: step by step. Breathe, 8(3), pp.232-240. [online] Available at: https://publications.ersnet.org/content/breathe/8/3/232. ERS PublicationsReddel, H.K. et al., 2021. Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes. European Respiratory Journal, 59(1):2102730. [online] Available at: https://erj.ersjournals.com/content/59/1/2102730. ERS PublicationsBMJ Best Practice, 2025. BMJ Best Practice: Info. [online] Available at: https://bestpractice.bmj.com/info/.Disclaimer: Please remember this video and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.
If you've got a penicillin allergy, this episode is crucial for you! That's because you can outgrow a drug allergy like this even if you developed it as an adult. Antibiotic allergies are either misdiagnosed or fade over time. Even if you avoid taking antibiotics like the plague, having a drug allergy on your medical chart can end up limiting treatment options if you find yourself truly needing them.In this episode, my guest, Dr. Mariana Castells, breaks down how drug allergies are diagnosed, how long they take to disappear, why they can appear later in life, and how “drug delabeling” could dramatically improve your care (especially when something serious happens). Dr. Mariana Castells, M.D., Ph.D., is a world-renowned expert in allergy and immunology with over 30 years of experience. Whether you have an antibiotic allergy (or you know someone who does), this is a must-listen interview!⭐️Mentioned in This Episode:- See all the references
Send me a question or story!It is very common for clients to present their pet to the veterinarian complaining that an allergy medication that used to work is no longer effective. Before changing therapies, it is important to consider four different things.1. Rule out simple mistakes like missed flea prevention, diet change, etc.2. Identify infection3. Progression of allergies4. It is no longer just allergiesLearn more details on this week's episode of The Derm Vet podcast!Timestamps00:00 Intro01:20 Looking for Simple Causes03:47 Identify Infections06:10 Allergy Progression08:30 When It Isn't Just Allergies10:22 Overview12:05 Outro
A healthy 47-year-old man from New Jersey suddenly died after delayed allergic reactions to red meat; it was later confirmed to be caused by alpha-gal syndrome (AGS), marking the first documented fatality linked to tick-driven mammalian meat allergy His symptoms began hours after eating beef following a recent camping trip, during which he sustained 12 to 13 suspected lone star tick bites — exposure to this tick is now known to trigger the immune sensitization that leads to AGS AGS occurs when the lone star tick introduces the alpha-gal sugar molecule into the bloodstream, causing the body to form antibodies and react severely, sometimes fatally, upon future consumption of mammalian meat or byproducts Cases of AGS are rising explosively across the United States, with documented diagnoses climbing from 12 in 2009 to more than 110,000 by 2022; estimates suggest over 450,000 Americans may be affected Experts warn that expanding tick ranges, misdiagnoses, and lack of awareness among healthcare providers are fueling this hidden public health threat, emphasizing the urgent need for preventive tick-bite strategies and proper tick removal techniques
This week, Chad and Kelsey try to help a couple where the wife recently developed an allergy to his semen, Kelsey spoils one of her Christmas presents and more! Write into pretendproblemspodcast@gmail.com with your dating and relationship advice questions and we'll answer them on the show! Subscribe to the podcast, and give it a 5-star rating and review to help the show move up the charts. Video for the episodes is on Kelsey’s YouTube channel! Join our Patreon: https://patreon.com/PretendProblems Watch the episodes and subscribe here: https://www.youtube.com/channel/UC9UBPfi4B_j1Ua7xDOcyBnA See Kelsey on tour: https://punchup.live/kelseycook/tickets See Chad on tour: https://punchup.live/chaddaniels/tickets Watch Kelsey's special “Mark Your Territory” on YouTube: https://youtu.be/uYqWsDhWkkA?si=J9hgt5nKtMLxB1sj Watch Chad's special "Mixed Reviews" on YouTube: https://www.youtube.com/watch?v=n1kVr3zkz7E&t=663s Follow Kelsey on social media: @KelseyCookComedy Follow Chad on social media: @thatchaddaniels Theme Song cowritten by Matthew Facca and Alex Bent
In this episode, host Dr. Dan Beswick speaks with Dr. Waleed Abuzeid. They discuss the recently published Original Article: “Predicting Surgical Outcomes in Chronic Rhinosinusitis From Preoperative Patient Data: A Machine Learning Approach.” The full manuscript is available in the International Forum of Allergy and Rhinology. Listen and subscribe for free to Scope It Out […]
In episode 63 of Going anti-Viral, Dr Mari Kitahata joins host Dr Michael Saag to discuss the role of outcomes research on clinical decisions for patient care. Dr Kitahata is a Professor of Medicine at the University of Washington (UW) in the Division of Allergy and Infectious Diseases. For more than 3 decades, she has directed the UW/Fred Hutch Center for AIDS Research (CFAR) Clinical Research Core. Dr Kitahata's research focuses on improving long-term outcomes for people with HIV and she has led studies demonstrating key determinants of increased survival in people with HIV including early initiation of antiretroviral therapy and care managed by physicians with greater HIV experience. Dr Kitahata discusses the significance of outcomes research in clinical settings, particularly in the context of HIV care. She explains the differences between efficacy and effectiveness, the challenges faced in observational studies, and the importance of statistical techniques to address biases. Dr Kitahata and Dr Saag discuss the role of electronic medical records (EMRs) in enhancing data collection and the necessity of data validation through adjudication processes. Additionally, the conversation touches on the importance of patient-reported outcomes and the limitations of EMR data, including issues of misclassification. Finally, Dr Saag and Dr Kitahata discuss the distinction between predictive modeling and etiologic modeling in research, underscoring the complexities of clinical care and the future directions for outcomes research.0:00 – Introduction2:30 – Efficacy versus effectiveness5:51 – Challenges in outcomes research8:27 – Statistical techniques in observational studies16:13 – The role of electronic medical records19:36 – Patient-reported outcomes and their importance22:18 – Data validation and adjudication28:30 – Limitations of observational data35:08 – The future of outcomes research __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...
Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Fei Li Kuang, MD, PhD, an allergist and immunologist, at Northwestern Medicine, about receiving two APFED HOPE on the Horizon Grants. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own. Key Takeaways: [:50] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz. [1:14] Holly introduces today's topic, two APFED HOPE on the Horizon Pilot Grant Projects and today's guest, Fei Li Kuang, MD, PhD, an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, Illinois. [1:42] Dr. Kuang is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples. Holly thanks Dr. Kuang for joining us. [2:05] As a child, Dr. Kuang always wanted to be a scientist. She is so grateful to live out her childhood dream, and it's because of the amazing people who have supported her, most importantly, her parents. [2:29] In graduate school, Dr. Kuang studied B cells. When she went on to do an allergy fellowship, she thought she would study B cells and care for patients with B cell problems. Instead, she fell in love with allergy and eosinophilic disorders. [2:50] Dr. Kuang is here, in part, because of the different mentors she has had, and in large part, because of the patients she has met along the way. [3:20] Dr. Kuang had the opportunity to work with Amy Klion at the NIH in a clinical trial to treat patients with a drug that gets rid of eosinophils. She says it was a dream come true after her training. [4:02] She says she learned so much about eosinophils, their unusual biology, and the mystery behind what they are here for. She got hooked. [4:15] Dr. Kuang thinks the patients you meet in a clinical trial in a special place like NIH occupy a space in your heart that makes you want to keep working on the subject area. [4:34] Patients in a clinical trial have given up a bunch of their time to travel to Bethesda, Maryland. For the trial Dr. Kuang participated in as a Fellow, it was a good year of their time to come out and do it. [4:47] Dr. Kuang felt there were so many interesting questions, from an intellectual point of view, but there was also a real need from patients with chronic conditions. It was a beautiful opportunity to marry scientists with physicians in training. [5:36] Dr. Kuang shares some knowledge about eosinophils. They are white blood cells that are in all of us. They have little pink packages or granules that "jumped out" in the light microscope almost 200 years ago, when we first identified them. [6:00] Dr. Kuang says that animals, dating back to reptiles, and different species of dolphins, all have eosinophils. A veterinary scientist, Dr. Nicole Stacy of the University of Florida, has taken photos of eosinophils from all these different species. [6:21] They've been around for a long time. What are they good for? What we know is that they are associated with disease conditions, such as asthma and others, including leukemia. Those were the classic first studies of eosinophils. [6:42] Now, we have a different mindset about eosinophils from work by the late James Lee at Mayo Clinic, Arizona. [6:58] Dr. Kuang credits Dr. Lee with suggesting that eosinophils not just cause us problems but also help treat parasitic infections, maintain tissue homeostasis, help wound healing, and tissue repair. That's a new area we are beginning to appreciate. [7:41] Dr. Kuang says we need to be open-minded that in some circumstances, eosinophils may be helpful or innocent. Now we have tools to start to understand some of that. We need to collect information from patients being treated with medicines. [8:10] Ryan tells of being diagnosed as a kid. Doctors explained to him that eosinophils fight parasites, but in some people, they get confused and attack the esophagus. That's EoE. That was easy to understand, but he knew that the researchers knew more. [8:53] Ryan is grateful to the patient population around eosinophilic esophagitis, and is proud of APFED's support of patients and caregivers with HOPE Grants. APFED has the HOPE on the Horizon Research Program, entirely funded by community donations. [9:13] To date, APFED has directed more than $2 million toward eosinophilic disease research initiatives through various grant programs. As a patient advocacy organization, APFED works with fantastic researchers who submit innovative research ideas. [9:32] These research ideas go through an extensive and competitive peer-review process, supported by researchers and clinicians in the APFED community. [9:42] Today, we're going to discuss two different projects supported by HOPE Pilot Grants with Dr. Kuang. [10:00] Dr. Kuang thinks there are two ways these grant programs are important to patients. One is advancing research by nurturing seedling investigators. Dr. Kuang got her first grant when she was a Fellow. It was an incredible opportunity. [10:25] These grant programs also nurture seedling ideas that don't have enough evidence yet to garner the larger NIH grants, and so forth. There are other sources for grants: pharmaceutical companies. The grant programs are for seeds. [10:49] Patients need to know that there are new things that are given some chance of being tested out. Research takes some time, and the FDA process of getting a drug approved is long. [11:04] For the newly diagnosed patient, it can feel overwhelming. It feels like there's a loss of control. Sometimes, participating in something like APFED, being part of a community, gives back a sense of control that is lost when you're handed a diagnosis. [11:45] For patients who have had it for a long time, when they participate in research and become engaged in organizations like APFED, they know they may not directly benefit today, they may benefit later, but they hope future patients will benefit. [12:21] That gives them a sense of control and hope that things will be better for the next generation. We all want that, especially in medicine, in something that we don't have a very deep understanding of. [12:58] Dr. Kuang received two HOPE Pilot Grants, one in 2018 and one in 2022. The first grant was awarded when she was a Fellow at the NIH. [13:05] That first grant explored some effects of eosinophilic depletion of pathogenic lymphocytes in hypereosinophilic syndrome and overlaps with EGIDs. Ryan asks for a broad overview of that research. [13:25] When Dr. Kuang was a Fellow at the NIH, they were doing a Phase 2 clinical trial, looking at "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients. [13:39] They included patients who had eosinophilic GI disease, often beyond the esophagus. They may have esophageal involvement, but sometimes their stomach is impacted, sometimes their large bowel is impacted, with related symptoms. [13:57] What Dr. Kuang and the team noticed in the trial was that just within that little group of patients, there were people who did well, and people who did much better than before, but would have recurrent symptoms, and with no eosinophils in their GI tissues. [14:16] The researchers wanted to know what was causing these problems for the patient. If you take eosinophils away, what other factors will impact the immune system of the patient, semi-long-term? [14:32] Their focus was on these groups of patients who had different responses. They looked at the white blood cells that had been previously described as being the responsible, "bad" T cells that lead to eosinophils in the gut. [14:49] They found that the patients who had recurrent flares of the disease had more of the bad T cells, and the patients who responded well and never complained again about symptoms did not. [15:03] That allowed researchers to identify that there were subsets of patients with the disease that they were calling the same thing. [15:18] Dr. Kuang says that work also led them to find that those cells were being reported in patients who had food allergies for which they needed an epinephrine auto-injector. [15:27] The researchers were curious whether that was just a food allergy issue, or only applied if you had food allergies and eosinophilic GI disease. That HOPE project allowed them to do a pilot study to look at food allergy patients, too. They did, and published it. [15:45] They published that in patients who have a food allergy and have these T cells, the insides of those cells make different messages for the immune system than the ones that the researchers had previously described. [16:01] In looking for why there were differences in those responses, they accidentally found that there were differences inside these cells in a completely different disease, which also had these T cells. [16:21] Dr. Kuang says that the finding was kind of a surprise. If they had found anything in the eosinophilic GI disease patients, that would have been good. They also looked at the epithelial cells and the structure of the GI lining. [16:42] Even though there were no eosinophils in the GI lining in the patients who had been treated with a biologic that depleted eosinophils, their GI lining still looked like the GI lining of patients who had eosinophilic GI disease. [16:55] Dr. Kuang asked what was creating those spots. Our gut lining sheds, so there should have been an opportunity for the GI lining to turn over and look new. Something was there, making signals to create these spots. They did a different publication on that. [17:21] The data from the HOPE Pilot study allowed Dr. Kuang to apply for larger grants. It allowed her to propose to the company that made this drug, when they did the Phase 3 trial, to insert into that special study the study on eosinophilic GI disease. [17:48] Do patients with eosinophilic GI disease do better or worse on this drug, and how do the T cells look in that trial? That HOPE Grant gave Dr. Kuang the data to ask the drug company to give her money to study it in an international cohort of patients. [18:17] There were only 20 patients in that first NIH trial, who gave a year of their life, coming to NIH all the time. They continued to be in the study until the drug was approved for asthma. [18:28] Dr. Kuang says the main reason the company did the Phase 3 trial, which is expensive, and the market share is not huge because it's a rare disease, is that two of the patients went to bat for this disease population. [18:47] The two patients went and showed the business people what they looked like before, what the drug had done for them, and how their lives had changed. It wasn't the doctors or the great paper from the trial, but the patients who convinced the company. [19:01] Dr. Kuang says she was so floored by that and moved by what they did for the community. She is grateful. [19:24] Since the Phase 3 trial, Dr. Kuang and the other researchers realized they had not fully studied the eosinophils. They had studied them in part. They found differences in response. This inspired the second APFED HOPE Pilot Grant. [21:19] In 2022, Dr. Kuang received a two-year APFED HOPE Pilot Grant to examine how blood eosinophils in Eosinophilic Gastrointestinal Diseases differ from those of other eosinophilic diseases and how T cells in EGIDs differ from those in food allergies. [21:49] Dr. Kuang says normally, the biggest place of residence for eosinophils is the GI tract. That's where they are normally seen in people who do not have eosinophilic disorders. [21:59] People who have eosinophilic disorders that attack other parts of the body, asthma, and rarely, the heart. Dr. Kuang was curious to know why one person and not the other? [22:15] Patients who have eosinophilic GI disease often ask, How do you know this high level in the blood is not going to attack my heart or my lungs in the future? Dr. Kuang does not know. [22:29] Dr. Kuang says, looking at the cohort at the NIH, that for many patients who have both GI organ involvement and some other space, when they first went to see a provider, their first complaint was a GI condition. [22:54] If the doctor had only diagnosed a GI condition, nothing else, that would have been wrong. Those patients may not have been monitored as well. A third of the patients originally presented like that. [23:11] What that meant was that we should be paying attention to patients who have GI disease who have lots of eosinophils in their blood. Moving forward, if there are new complaints, we need to investigate. We can't forget they have that. [23:27] Dr. Kuang asks, Wouldn't it be great if we had a better tool than needing to wait? Wouldn't it be great if we had a biomarker that said the eosinophils have switched their target location and are going somewhere else? [23:41] One way to do that is to take different groups of eosinophils and look for differences between those that never target the GI tract and those that do. In patients who have EoE, the eosinophils only target or cause problems in the esophagus. [23:58] Are their eosinophils any different than those of a healthy person, with none of these conditions? That was the goal of that study. [24:10] T cells are another type of white blood cell. They contain a memory of foreign things they have encountered, which allows them to glom onto flu, COVID, peanuts, pollen, that kind of thing. They remember. [24:32] Dr. Kuang says they learned that T cells, at least in the mouse model, are required in the development of eosinophilic esophagitis. The mice in the old study, where mice were forced to develop EoE, did not get EoE if you removed their T cells. [24:50] In the first APFED HOPE grant study, Dr. Kuang found T cells in the blood and tissue of both EGIDs and food allergy patients, but the insides of the T cells were different. The food allergy patients were children recruited by a pediatric allergist. [25:19] In the second APFED HOPE grant study, at Northwestern, Dr. Kuang recruited her adult food allergy patients. That was a way to validate what they found in the first study and move further to better characterize those T cells in the two different diseases. [25:47] Dr. Kuang says we're at a point where we've recruited a lot of people. She says it's amazing what people are willing to do. It's very humbling. [26:06] Dr. Kuang's team in the lab is really great, too. To accommodate patients, they would see them after work, if that's what they had to do to isolate eosinophils. So they did that, and now they are in the process of analyzing that data. It's really exciting. [26:28] What's exciting is that they are seeing results that show that eosinophilic GI disease patients have circulating eosinophils that are different from the eosinophils of people who don't have GI involvement, and from people who have EoE. [26:46] The EoE patients have eosinophils different from those of healthy donors. Dr. Kuang says there's a lot of promise for perhaps unique signatures that could help define these conditions; maybe someday without biopsying, but that's a long time away. [27:16] Dr. Kuang says they will focus on some candidate targets and try to recreate some of that in a dish with eosinophils from healthy people. [27:26] What are the signals that lead eosinophils to do this, and can we translate that back to available drugs that target certain cytokines or other pathways, and maybe give some insight to develop drugs that target other pathways for these diseases? [28:17] Ryan thinks it's exciting that this research is narrowing in on not only the different symptoms, but also how the eosinophils are acting differently in these populations. [28:44] Dr. Kuang is super excited about this research. You could imagine that all eosinophils are the same, but you don't know until you look. When they looked, using the newest technology, they found there were differences. [29:33] Dr. Kuang says it is thought that T cells respond to triggers. We don't think eosinophils have a memory for antigens. T cells do. That's one of their definitions. When T cells react to a trigger, they give out messages through cytokines or by delivery. [30:20] Those are the messages that recruit eosinophils and other cells to come and stir up some trouble. [30:28] In the mouse model, where you don't have the T cells, and you don't get eosinophilic esophagitis in the particular way they made it happen in a mouse, that middle messenger is gone, so the eosinophils don't know where to go. [30:44] With drugs that take out eosinophils, you think that you've gotten rid of the cell that creates all the problems. It shouldn't matter what the message says because there's no cell there to cause the damage. [30:58] What Dr. Kuang learned is that, at least in certain eosinophilic GI diseases, that's not true. You erase the eosinophils from the picture, but that message is still coming. [31:10] Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there? [31:24] It's important to study both, because one is the messenger and the other is one of the actors. Whether all of the actions taken by eosinophils are bad, or maybe some of them were meant to be good, we have yet to learn. [31:40] At the moment, we're using it as a marker for disease activity, and that may change in the future, as we learn more about the roles of these cells in the process. [31:50] We have drugs now that target eosinophils and drugs that target T cells. Dr. Kuang thinks it's important to study both and to study the impact of these drugs on these cells. [32:02] You could theoretically use these drugs to understand whether, if someone responds to it, what happens to these cells, and if someone doesn't respond to it, what happens to these cells, and how this disease manifests in this flavor of patients. [32:54] Dr. Kuang says, Often in science, we take a model. We think this works this way. Then, if this works this way, we expect that if we remove this, these things should happen. We did that with the first clinical trial, with NIH patients. [33:10] It didn't quite happen the way we thought, so we had to go looking for explanations. These were unusual setbacks. Sometimes you have unusual findings, like the food allergy part. [33:24] When Dr. Kuang went to Northwestern, she saw different cohorts of patients than she saw at NIH. She saw people who were seen every day, which is a different spectrum than those who are selected to be enrolled in a study protocol at the NIH. [33:42] That broadened her viewpoint. It's maybe not all food-triggered. They were seeing adults who'd never had food allergies or asthma their whole life, and they had eosinophilic esophagitis suddenly as a 50-year-old. There's a significant group of them. [34:10] What Dr. Kuang learned and tries to be open-minded about is that where you train, what sorts of patients you see, really shape your viewpoint and thinking about the disease process and the management process. [34:24] Dr. Kuang says she was so lucky to have experienced that at a quaternary care referral center like the NIH and at an academic center like Northwestern, where there are fantastic gastroenterologists who see so many of these patients. [34:56] Dr. Kuang and an Allergy Fellow knew they were going to get a wonderful data set from the NIH patients they had recruited, so they thought they had better look deeply at what had been learned before with older technology, with mice and people. [35:13] They decided to gather previous research, and that ultimately got published as an article. From that research, they learned that people did things in many different ways because there was no standard. They didn't know what the standard should be. [35:28] Different things you do to try to get eosinophils out of tissue impact how they look, in terms of transcript, gene expression, and what messages they make to define themselves as an eosinophil. [35:43] They also learned that because eosinophils are hard to work with, they die easily, and you can't freeze them and work on them the next day; you can introduce issues in there that have to be accounted for. [35:59] They learned that as an eosinophil research community, they ought to come up with some standards so that they can compare future studies with each other. Dr. Kuang says it was impossible to compare the old studies that used different premises. [36:50] Dr. Kuang says we need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data. It's hard to use the old data. [37:57] Dr. Kuang says they get fresh blood from patients, and because eosinophils are finicky, they need to be analyzed within four hours, or preserved in a way to save whatever fragile molecules are to be studied. [38:19] If you let it sit, it starts dying, so you won't have as many of them, and they start changing because they're not in the body. Dr. Kuang experimented with putting a tube of blood on the bench and checking it with the same test every two hours. It changes. [38:38] Four hours is a standard to prevent the eosinophils from dying. Patients need treatment. If a patient is hospitalized and needs treatment, Dr. Kuang's team needs to be there to get a sample before treatment is started. [39:03] The treatment impacts it, changing the situation. Much of the treatment, initially, is steroids. When you give lots of steroids, the eosinophils go away. It's no good to draw their blood then. [39:27] Dr. Kuang also gets a urine sample. The granules of the eosinophils can get into the urine. As they study people with active disease, they want to capture granule proteins in the urine as a less invasive way to monitor activity in different disease states. [40:04] The patient just needs to give Dr. Kuang either arm and a urine sample. [41:04] Dr. Kuang explains, you can count your eosinophils after four hours, but to study them, they have different flags of different colors and shapes. Those colors and shapes may mean that it's an activated eosinophil, or they may have other meanings. [41:41] Dr. Kuang focused on markers that look at whether it's going to spill its granules and some traditional markers of activation. [41:50] Everyone chooses a different marker of activation. So they decided to look at as many as they could. One marker is not sufficient. They seem to be different in different conditions. The markers are on the surface; you need to analyze them right away. [42:20] Then, Dr. Kuang breaks open the eosinophils and grabs the messenger RNA. They preserve it to do sequencing to read out the orders to see what this eosinophil is telling itself to make. RNA chops up messages. [43:00] When you open an eosinophil, a protein you find is RNA, which chops up messages, destroying parts of the cell. You want to save the message. There's a brief time to analyze the eosinophil. Dr. Kuang works to preserve and read the message. [44:04] Dr. Kuang hopes someday to run a tube of blood, look at the flags on the eosinophils, and say, "I think your eosinophilic GI disease is active," or "You have a kind of eosinophilic GI disease we need to monitor more frequently for organ damage." [44:38] If another patient doesn't have those flags, Dr. Kuang could say, "I think the chances that you're going to have involvement elsewhere are low." That can give reassurance to folks who are worried. [45:15] Dr. Kuang hopes that someday we can understand better why some people have food allergies vs. eosinophilic GI disease. They both have T cells, but the T cells have different packages inside with messages to deliver. [45:34] Every day, Dr. Kuang has to tell patients she doesn't have that answer. Someday, she hopes she can tell a patient she does have that answer. [46:35] Dr. Kuang tells about an NIH grant she's excited about and the patients she recruits after therapy, or elimination diets, to examine eosinophils and T cells, to see the impacts their treatments or diets have had on eosinophilic GI disease. [47:18] Dr. Kuang believes there will be predictors of who will respond to an elimination diet and who will respond to steroid therapy. She hopes one day to have that, rather than going through rounds of six to eight weeks followed by a scope. [47:34] If you have an elimination diet for six to eight weeks, every time you add back a food, you have to do a scope. Dr. Kuang says it would be great if you could be more precise ahead of time for therapy. [47:48] Dr. Kuang says these wonderful drugs selectively take out parts of the pathway in the immune system. They provide real-life opportunities to ask, why is this important in human biology and the human immune system? [48:15] Dr. Kuang finds the knowledge itself fascinating and useful. She hopes it informs how we choose future drugs or therapeutic avenues to get the best we can out of what we've learned, so we have more targeted ways of treating specific diseases. [48:48] Ryan is grateful for all the research happening for the eosinophilic disease community and all the patients participating in the research. He asks Dr. Kuang how a patient can participate in research. [49:12] There are lots of ways to be involved in research. Dr. Kuang says her patients come away from participating in research feeling good about having done it. [49:22] Answer a survey, if that's what you have bandwidth for. Where therapies are changing, being a part of a community is good for the community, for the future, but it's good for you, too. It's healing in ways that are not steroids or biologics. [49:58] Being part of a community is healing in ways we all need when we feel alone and bewildered. You're not alone. [50:12] There are many ways to participate: APFED, CEGIR, individual institutions, and clinical trials. They all have different amounts of involvement. It's worthwhile to participate, not only for future patients but for yourself. They're fantastic! [50:56] Dr. Kuang talks about the privilege as a physician of working with APFED and other organizations to do this work. [51:09] Holly thanks Dr. Kuang for sharing all of this research and exciting information. [51:25] Dr. Kuang is excited about what her group is doing and is hopeful. Besides showing up for this disease, we have to show up for research, in general, in this country. It's a dark time for NIH research funding. [51:55] Dr. Kuang asks the young listeners who are thinking of choosing a field to see the potential and get into it, study this, and believe that there's going to be a future with a more nurturing research environment. [52:36] Dr. Kuang would hate to lose generations of scientists. She says that once she was a little girl who was trying to be a scientist. Her parents had no connections with scientists or doctors, but she was able to get into research, and she thinks you can, too. [53:48] As a graduate student, Ryan has always been interested in trying to improve things, and he sees hope on the horizon. He's very grateful to the APFED community for supporting these research HOPE Pilot Grants. [54:17] Ryan is very grateful to Dr. Kuang for joining us today. [54:22] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes. [54:28] If you're looking to find a specialist who treats eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist. [54:37] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections. [54:57] Dr. Kuang thanks Ryan and Holly and says she enjoyed the conversation. Holly also thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Mentioned in This Episode: Fei Li Kuang, MD, PhD, Allergist and Immunologist, Northwestern Medicine Grants and publications discussed: Apfed.org/blog/apfed-announces-2018-hope-apfed-hope-pilot-grant-recipient/ Apfed.org/blog/fei-li-kuang-hope-pilot-grant-award/ Pubmed.ncbi.nlm.nih.gov/39213186/ Pubmed.ncbi.nlm.nih.gov/37487654/ APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda. Tweetables: "I think the patients that you meet in a clinical trial, especially in a special place like NIH, occupy a space in your heart — I don't mean to be all too emotional about this — that makes you want to keep working on the subject area." — Fei Li Kuang, MD, PhD "When I was a Fellow at the NIH, we were doing a Phase 2 clinical trial, looking at, for want of a better word, "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients." — Fei Li Kuang, MD, PhD "We're at a point where we've recruited a lot of people. I've had patients drive from the northern part of Illinois … come down and give me blood. It's amazing what people want to do and are willing to do. It's very humbling, actually." — Fei Li Kuang, MD, PhD "You erase the eosinophils from the picture, but that message is still coming. Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?" — Fei Li Kuang, MD, PhD "We need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data." — Fei Li Kuang, MD, PhD "I think it's worthwhile to participate [in a clinical trial], not only for the future people but for yourself." — Fei Li Kuang, MD, PhD Guest Bio: Fei Li Kuang, MD, PhD, is currently an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She is a graduate of the Albert Einstein College of Medicine Medical Scientist Training Program with both a PhD in Cell Biology/Immunology and an MD. She completed her Internal Medicine Residency at Columbia University, New York Presbyterian Hospital in New York City, she did her Fellowship in Allergy and Immunology at the National Institute of Allergy and Infectious Disease (NIAID) in Bethesda, Maryland. She is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples.
The pros and cons of natural vs synthetic vitamins; Telehealth site for ADD meds lands founder in prison; Why eradicating H. pylori may set the stage for Alzheimer's; Why integrative physicians often don't accept insurance; Far-infrared phototherapy may offer “electroceutical” treatment for dementia; Hobbies may forestall all-cause mortality—by 29%!
A recent report of a man dying after eating a hamburger has catapulted the Lonestar Tick into the news. Can the saliva of a tick cause an aversion to meat so much as to the point of death? How does this play into the plans of the WEF, UN, WHO and many others to restrict people from eating meat? What if they have already told us what they would like to do with this tick. They actually have and as you would suspect, it isn't good.....Email us at: downtherh@protonmail.com
This week, Danielle and Kristine learn how to survive exposure to sulfuric acid — trust us, you don't want to mess around with this chemical. Then Jeremy Bent joins to share the unfortunate way he discovered he's allergic to sulfa-based antibiotics.
Clonal mast cell disease is often missed because symptoms vary from person to person, tryptase levels can be normal, and bone marrow biopsies are hard to get. For some people, unexplained or very severe anaphylaxis may be an early sign of a clonal mast cell disease. In this episode, we review “Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation,” published in October 2025 in the Journal of Allergy and Clinical Immunology. This paper, known as the PROSPECTOR trial, is looking at how often the KIT D816V mutation can be found using a blood test in adults who have had anaphylaxis or systemic mast cell activation symptoms. We break down why KIT D816V matters, how it connects to systemic mastocytosis, why HaT needs to be considered, and how newer blood tests may help doctors catch clonal mast cell disease earlier. What we cover in our episode about KIT D816V and anaphylaxis: Setting the stage: Understanding mast cell activation and anaphylaxis. Why KIT D816V matters: How this mutation fits into clonal mast cell disease, what blood testing can reveal, and when doctors still turn to a bone marrow biopsy. Making sense of tryptase and hereditary alpha-tryptasemia (HaT): Why baseline tryptase, the “20% + 2” rule, and HaT can make screening more complicated than it seems. What the PROSPECTOR trial uncovered: How often KIT D816V appeared in people with anaphylaxis, and other results on tryptase and HaT. How this helps patients: What these findings mean for anyone with unexplained or severe anaphylaxis, and how doctors combine KIT testing, tryptase, HaT, and symptoms to decide on next steps. Other podcast episodes about mast cell disease: Ep. 127: Management of indolent mastocytosis - A clinical yardstick Ep. 126: Management of mast cell activation syndrome - A clinical yardstick Ep. 121: Avapritinib vs Placebo in Indolent Systemic Mastocytosis - PIONEER Trial Ep. 118: The ISM Disconnect - Do Patients and Providers Agree on Symptom Control? Ep. 70 How do stress and low histamine diets impact mast cell disease? Ep. 63: Mast Cell Diseases & Systemic Mastocytosis: The Basic Science Ep. 65: The Symptoms and Triggers of Mast Cell Disease *********** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Blueprint Medicines for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
In this conversation, we pull back the curtain on alpha-gal syndrome diagnostic testing at Thermo Fisher Scientific with Gary Falcetano, PA-C. Gary shares insights into how the alpha-gal syndrome test works and answers some of our most frequently asked questions. How do you talk to your provider about being tested? Is the test covered by insurance? What provider can order the test? He also dives into how Allergy Insider, Thermo Fisher's patient resource, is bringing alpha-gal into the conversation. Tune in now to learn more! Gary Falcetano, PA-C, serves as Senior Manager Global Medical and Scientific Affairs for allergy at Thermo Fisher Scientific. Gary has been a Board Certified Physician Assistant for over 28 years, and is the host of Allergy Insider's ImmunoCAST podcast.Visit Allergy Insider to learn more about their patient resources and be sure to follow on social media: @allergyinsider
The Rich Zeoli Show- Hour 4: 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a massive attempt to suppress the truth about Covid-19's origins. 6:40pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams.
The Rich Zeoli Show- Full Show (12/03/2025): 3:05pm- A report from Ernesto Londono of The New York Times documents rampant fraud plaguing Minnesota—dozens of people have been charged with stealing more than $1 billion in taxpayer money from programs meant to feed hungry children and provide therapy for autistic children. Critics of Governor Tim Walz say his administration allowed the fraud to persist “partly because state officials were fearful of alienating the Somali community” who were largely responsible for the scams. 3:10pm- While speaking with the press on Tuesday, President Donald Trump called for a reduction of migrants from third world countries who are openly unwilling to assimilate to American culture. 3:20pm- Philadelphia Highway Patrol Officer Andy Chan has died six years after he was struck by a vehicle while on duty. Rich notes that Officer Chan was a friend of the show. Next Friday the show will be broadcasting from the 6th Annual Andy Chan Holiday Block Party. 3:30pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. 4:05pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 4:40pm- Carrie Severino—President of the Judicial Crisis Network (JCN) & Co-Author of the book, “Justice on Trial: The Kavanaugh Confirmation and the Future of the Supreme Court.”—joins The Rich Zeoli Show. On Tuesday, the U.S. Supreme Court heard oral argument in First Choice Women's Resource Centers v. Platkin. The case asks whether a federal court can hear First Choice's First Amendment challenge to a New Jersey investigatory subpoena when no state court has yet ordered the group to comply. While being questioned by Justice Clarence Thomas, NJ Attorney General Sundeep Iyer conceded that NJ hasn't received any public complaints to justify its subpoena against the pro-life health center. 5:05pm- A Washington Post report states that Department of War Secretary Pete Hegseth authorized a series of deadly strikes on a drug trafficking boat in the Caribbean, ordering military officials to “kill everybody.” The directive, according to the report, led to a second strike killing several crew members that survived the initial assault on the vessel. The New York Times, as well as the White House, dispute that Hegseth explicitly authorized the second strike or ordered to eliminate survivors. The NYT also reports that the “U.S. military intercepted radio communications from one of the survivors to what [officials] said were narco-traffickers.” 5:30pm- Following the Eagles loss to the Bears on Friday, Offensive Coordinator Kevin Patullo had his house egged. Does Justin have an alibi? Plus, a drunk racoon ransacked a convenience store! And “Be Nice to Matt Week” continues…sort of… 6:00pm- Speaking from the Oval Office, President Trump, alongside Transportation Secretary Sean Duffy, announced a repeal of onerous fuel efficiency regulations put in place under the Biden administration. They had been designed to artificially boost electric vehicle manufacturing and sales. Trump described the policy shift as a win for consumers—as the previous efficiency standards led to higher prices on new vehicles. 6:30pm-While speaking with New York Post reporter Miranda Devine, FDA Director and Johns Hopkins surgeon Dr. Marty Makary documented the ways former Director of the National Institute of Allergy and Infectious Diseases Dr. Anthony Fauci was involved in a ma ...
In Australia, 1 in 10 families are navigating life with food allergies - and the anxiety that comes with keeping children safe can be overwhelming. In this essential conversation, Dr. Jodi Richardson welcomes Tamara Hubbard, founder of the Food Allergy Counselor and author of May Contain Anxiety: Managing the Overwhelm of Parenting Children with Food Allergies.Tamara is pioneering mental health support in food allergy care, helping families find what she calls the "just right balance" between anxiety and quality of life. As both a therapist specialising in food allergies and a parent who walks this path herself, she brings unique insight into the daily challenges families face - from label reading and school lunches to managing the fear of anaphylaxis.In this episode, you'll discover:Why anxiety is a natural part of food allergy management (and when it becomes overwhelming)The powerful "what if to if-then" strategy for managing worried thoughtsHow to determine what's safe, safe enough, and not safe for your childWhy avoidance can extend beyond what's medically necessaryThe importance of having your healthcare team answer key safety questionsHow families can live full, rich lives despite food allergy diagnosesWhether you're newly navigating a food allergy diagnosis, supporting someone who is, or simply want to understand what these families experience daily, this conversation offers hope, practical strategies, and validation for the very real challenges of keeping children safe while helping them thrive.Book Release: May Contain Anxiety is available now in North America in hardcover, paperback, e-book, and audiobook formats. Australian print editions are expected in early 2025, with digital versions available now.Connect with Tamara: Visit foodalergycounselor.com for resources, articles, and therapeutic worksheets, or follow @foodallergycounselor on social media.See omnystudio.com/listener for privacy information.
In this episode we dive into the strange and fascinating world of Alpha-gal syndrome (AGS), the delayed meat allergy that can appear after a tick bite. We talk through what AGS actually is, how ticks (lone star, blacklegged and western blacklegged ticks) introduce it into the body, and why some people develop an allergic reaction hours after eating red meat. You will hear about the symptoms people notice most often and the practical steps you can take to protect yourself from this unusual tickborne illness.Citations: A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner - PMCAbout Alpha-gal Syndrome | Alpha-gal Syndrome | CDCPreventing Tick Bites | Ticks | CDCWhat You Need to Know about PermethrinWhat to Do After a Tick Bite | Ticks | CDCRepellents: Protection against Mosquitoes, Ticks and Other Arthropods | US EPALegal:This podcast is for informational and educational purposes only and should not be taken as medical advice, diagnosis, or treatment. Nothing in this episode should be used to make decisions about your health without consulting a licensed physician or qualified healthcare professional. If you have questions about symptoms, allergies, prevention strategies, or medical conditions, please speak directly with your healthcare provider.All views expressed in this podcast are my own and do not represent the views of any current or past employers, academic institutions, or professional organizations. This podcast does not establish a clinician–patient relationship, and the use of the information discussed is at your own risk. If you are experiencing a medical emergency or severe allergic reaction, please seek immediate medical attention.
Bob Papa and Carl Banks preview the Monday Night Football matchup against the Patriots. With Mike Kafka shaking up the staff by firing Shane Bowen and elevating Charlie Bullen to interim defensive coordinator, they break down the changes fans should expect and why these moves matter for the team's future. They also dive into why playing strong down the stretch is critical and make the case for why Jaxson Dart needs more reps as the season unfolds. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next. Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest: Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices
On this episode: Lucy Lopez, Elizabeth Newcamp, and Zak Rosen are handing the show over to Slate's news podcast, What Next. Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest: Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now atslate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices
Craig Fontenot and Dr. Kelly Cleary both work at Food Allergy Research & Education, or FARE — a national non-profit focusing on food allergies. They spoke about what people can do to make holiday gathering safe and more comfortable for everyone.
Allergies on the rise, epi pen access, childhood peanut exposure guidelines, and how allergens exposure doesn't mean let your child roll in the dirt. -o-www.everythingispublichealth.comBluesky Social: @everythingisPHMastodon: @everythingispublichealth Email: EverythingIsPublicHealth@gmail.com Photo Credit: Photo by Diana Polekhina on UnsplashSupport the show
On episode #94 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 11/11/25 – 11/19/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus (Science Translational Medicine) Hepatitis B reactivation following switch away from tenofovir-containing anti-retroviral therapy in people living with HIV: A case series and lessons for practice (CID) Antimicrobial drug-resistant Neisseria gonorrhoeae (GC) infections in men using doxycycline postexposure prophylaxis. A substudy of the ANRS 174 DOXYVAC trial (CID) HIV Pre-exposure Prophylaxis Does Not Increase Gonorrhea and Chlamydia Incidence in Young Black and Hispanic Men who Have Sex With Men: An Observational Cohort Study (OFID) Bacterial Global and regional knowledge of antibiotic use and resistance among the general public: a systematic review and meta-analysis (CMI: Clinical Microbiology and Infection) Infant Botulism Outbreak Linked to Infant Formula, November 2025 (CDC: Botulism) Outbreak Investigation of Infant Botulism: Infant Formula (November 2025) (FDA) Vitamin D deficiency at hospital admission with community-acquired pneumonia is associated with increased risk of mortality: A Prospective Cohort Study (OFID) Bat-Associated Hemotropic Mycoplasmas in Immunosuppressed Children, Spain, 2024 (Emerging Infectious Diseases) A Multicomponent Intervention to Improve Maternal Infection Outcomes (NEJM) Fungal The Last of US Season 2 (YouTube) Increasing Fluconazole Resistance in Candida parapsilosis: A 10-Year Analysis of Blood Culture Isolates at a US Reference Laboratory (2015–2024) (JID) British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update (LANCET: Infectious Diseases) In Vivo Evolution of Candida auris Multidrug Resistance in a Patient Receiving Antifungal Treatment (JID) Parasitic Implications of a fatal anaphylactic reaction occurring 4 hours after eating beef in a young man with IgE antibodies to galactose-α-1,3-galactose (JACI: Journal of Allergy and Clinical Immunology In practice) WHO recommends R21/Matrix-M vaccine for malaria prevention in updated advice on immunization (WHO) Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi (LANCET: Global Health) A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication? (PLoS Neglected Tropical Diseases) Miscellaneous IL12RB1 deficiency appearing in North America: expanding the clinical phenotypes (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.
Look beyond viral suppression to learn how people living with virologically suppressed HIV may still be candidates for antiretroviral therapy (ART) switch to improve treatment satisfaction and quality of life. Topics covered include:Reasons to consider regimen optimization in setting of viral suppressionAvailable switch regimens, including 2-drug regimens and long-acting ARTApproaches to assess for resistance before starting long-acting cabotegravir plus rilpivirine DHHS recommendations on proviral DNA genotypingART optimization strategies for patients living with viral suppression and history of underlying resistancePresenters:Brian R. Wood, MDProfessor of MedicineDivision of Allergy and Infectious DiseasesUniversity of WashingtonSeattle, WashingtonCristina Mussini, MDProfessor of Infectious DiseasesChief of the Division of Infectious Diseases, Policlinico, ModenaUniversity of Modena and Reggio EmiliaModena, Italy Link to full program and accompanying slides: https://bit.ly/4pAI66gGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, host Dr. Kristine Smith speaks with Mr. James Bates. They discuss the recently published Original Article: “A Phase 1 Research Trial to Evaluate the Safety and Effectiveness of Intranasal Botulinum Toxin Type A Spray for Patients With Rhinitis.” The full manuscript is available in the International Forum of Allergy and Rhinology. Listen […]
Get all the inside secrets and tools you need to help you develop your intuitive and leadership skills so you are on the path to the highest level of success with ease. Christine Lauer shares about her journey from IT Computer Programmer to Laser Acupuncturist! In this episode you will learn:Quest for solutionsHow lasers balance imbalancesYES! It can be done remotelyAbout Christine:Christine has been a trusted Nutritionist and Acupuncturist since 2005, specializing in helping people find natural relief for allergies and sensitivities. Her journey began when her daughter developed severe eczema. When traditional remedies failed, Christine took matters into her own hands. By blending modern and ancient healing methods, she was able to help her spouse's seasonal allergies & her daughter's cat allergy, fueling her passion to helping others achieve lasting relief.Connect:Facebook: https://www.facebook.com/christinelauer1111 If you are ready to start reaching your goals instead of simply dreaming about it, start today with 12minutegift.com! Grab your FREE meditation: Reduce Your Anxiety MEDITATIONAre you ready to tiptoe into your intuition and tap into your soul's message? Let's talk Listen in as Jennifer Takagi, founder of Takagi Consulting, Certified High Performance Coach, 5X time Amazon.Com Best Selling-Author, Certified Soul Care Coach, Certified Jack Canfield Success Principle Trainer, Certified Professional Behavioral Analyst and Facilitator of the DISC Behavioral Profiles, Certified Change Style Indicator Facilitator, Law of Attraction Practitioner, and Certified Coaching Specialist - leadership entrepreneur, speaker and trainer, shares the lessons she's learned along the way. Each episode is designed to give you the tools, ideas, and inspiration to lead with integrity. Humor is a big part of Jennifer's life, so expect a few puns and possibly some sarcasm. Tune in for a motivational guest, a story or tips to take you even closer to that success you've been coveting. Please share the episodes that inspired you the most and be sure to leave a comment. Official Website: http://www.jennifertakagi.comInstagram: https://www.instagram.com/jennifertakagi/Facebook: facebook.com/takagiconsulting I look forward to connecting with you soon,Jennifer TakagiSpeaker, Trainer, Author, Energy HealerPS: We would love to hear from you! For questions, coaching, or to book interviews, please email my team at Jennifer@takagiconsulting.com
In his weekly clinical update, Dr. Griffin and Vincent Racaniello are dismayed by the changes on CDC vaccine website positively stating the link between autism and vaccination, the finding of wild type poliovirus 1 in Germany, Marburg virus in Ethiopia, decimation of the elephant breeding colony by H5N1 and the first human case of H5N5 influenza virus infection before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, antibody escape by seasonal flu viruses, where to find PEMGARDA, how to access and pay for Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, if resistance exercise aids in recovery from long COVID and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Autism and Vaccines (CDC: Vaccine Safety) A new road to eradication- WPV 1 in Germany from Afghanistan (Reuters) Ethiopia confirms first outbreak of Marburg virus disease (WHO: Ethiopia) Highly Pathogenic Avian Influenza Viruses (HPAIV) Associated with Major Southern Elephant Seal Decline at South Georgia (Communications Biology) Avian flu has decimated world's largest breeding colony of southern elephant seals (CIDRAP) Washington resident is infected with a different type of bird flu (AP News) Pelagic Seabirds (OceanAminals) That sounds far away: Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals (Cell Reports) Regional voices, different choices: Parents' and caregivers' HPV vaccine attitudes in the northeast and Southeast United States (Vaccine) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Emergence of seasonal influenza A(H3N2) variants with immune escape potential warrants enhanced molecular and epidemiological surveillance for the 2025–2026 season (University of Toronto Press) Types of Influenza Viruses (CDC: Influenza (flu)) With an absent CDC and mismatched 'subclade K' flu strain, experts face upcoming season with uncertainty (CIDRAP) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-word global database (Journal of Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease (CID) FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy: FDA Safety Communication (FDA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) COVID-19 vaccination is associated with reduced complications in pediatric patients with atopic dermatitis (Annals of Allergy, Asthma and Immunology) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) Risk mitigation of shared room ventilation and filtration on SARS-CoV-2 transmission: a multicenter test-negative study (Infection Control and Hospital Epidemiology) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Resistance Exercise Therapy After COVID-19 Infection(JAMA Open Network) Reaching out to US house representative Letters read on TWiV 1272 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists
Are any people particularly susceptible to alopecia-linked hair loss? Also, what causes eczema and why does it keep recurring, why are the progeny of different species infertile, why does hair go grey but not always symmetrically, and Is asthma a risk factor for bronchitis? Plus, are zebras actually black with white stripes, or white with black stripes?! Join Dr Chris Smith and Clarence Ford to Ask the Naked Scientist... Like this podcast? Please help us by supporting the Naked Scientists
Persistent congestion, pressure, or a reduced sense of smell often gets mistaken for allergies or a stubborn cold when it may be something more, like chronic rhinosinusitis with nasal polyps (CRSwNP). Getting the right diagnosis is the first step toward real relief. Dr. Tonya Farmer, a board-certified ENT, joins Kortney and Dr. G to explain how chronic rhinosinusitis with nasal polyps (CRSwNP) is diagnosed. She walks us through the full evaluation: what symptoms matter, what a nasal endoscopy actually shows, when a CT scan is needed, and how type 2 inflammation fits into the picture. What we cover about diagnosing CRSwNP: Key symptoms: Persistent congestion, drainage, facial pressure, and especially loss of smell are major red flags for CRSwNP. Why duration matters: Chronic means 12 weeks or longer. If symptoms keep coming back or never truly improve, it's time to look deeper. The physical exam: ENTs use nasal endoscopy to see swelling, mucus, or polyps that aren't visible from the outside. When CT scans are needed: Imaging helps confirm sinus inflammation and shows the extent of polyp growth. Additional testing: Allergy testing, IgE levels, eosinophils, and other immune markers help identify type 2 inflammation and guide next steps. When to see a specialist: If antibiotics, steroids, or over-the-counter treatments aren't helping, ask for a referral to an allergist or ENT. Early diagnosis can prevent worsening symptoms and reduce the need for surgery. Set the foundations: Ep. 133: What is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)? ___ Made in partnership with The Allergy & Asthma Network. Thanks to Sanofi for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.
Hardware is… easy now?! That's what Matt Truebe said when he pitched three devices and a plan to help families with food allergies and asthma. He has tons of experience, but between telehealth and hardware, is this business just too complicated for the VCs? This is The Pitch for Above Health. Featuring investors Cyan Banister, Charles Hudson, Immad Akhund, Monique Woodard, and Rohit Gupta. ... Watch Matt's pitch uncut on Patreon (@ThePitch) Subscribe to our email newsletter: insider.pitch.show Learn more about The Pitch Fund: thepitch.fund *Disclaimer: No offer to invest in Above Health is being made to or solicited from the listening audience on today's show. The information provided on this show is not intended to be investment advice and should not be relied upon as such. The investors on today's episode are providing their opinions based on their own assessment of the business presented. Those opinions should not be considered professional investment advice. Learn more about your ad choices. Visit podcastchoices.com/adchoices
Earlier this month, more than 2,500 allergists and healthcare professionals gathered in Orlando, Florida, for the annual meeting of the American College of Allergy, Asthma & Immunology—better known as ACAAI. It's one of the biggest events of the year where experts share the latest research, treatments, and guidelines in allergy and immunology. We're thrilled to be joined by this year's keynote speaker, program chair—and FAACT Medical Board Member—Dr. Kristin Sokol, MD, MS, MPH, who shares highlights and key takeaways from this cutting-edge meeting.Resources to keep you in the know:American College of Allergy Asthma and Immunology (ACAAI)Schreiber Allergy: Kristin Sokol, M.D., MS, MPH, FACAAI, FAAAAIYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: GenentechThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!
Send me a question or story!As dermatologists, we LOVE topical therapy. However there are some basic things that need to be considered when suggesting a protocol. What are you treating?What is the ultimate goal?What do you or the owner have?Can it happen?Check out some simple tips on this week's episode of The Derm Vet podcast!00:00 – Intro01:15 – Q1: Why Are You Using Topical Therapy?04:41 – Q2: What is the Goal of the Product?05:58 – Q3: What Do You Have Available?08:45 – Q4: Can the Owner Do It?11:34 – Overview12:44 – Outro
The tickborne illness alpha-gal syndrome affects what you can eat. For those who contract it, mealtime becomes a minefield. Plus: American agriculture depends on foreign workers, but President Donald Trump's immigration clampdown is shrinking a farm workforce that many say was already too small.
FULL SHOW: Tuesday, November 11th, 2025 Curious if we look as bad as we sound? Follow us @BrookeandJeffrey: Youtube Instagram TikTok BrookeandJeffrey.comSee omnystudio.com/listener for privacy information.
For years, doctors warned parents to keep peanuts away from children until they turn three. But that advice backfired. Experts now say delayed exposure helped cause a peanut allergy surge in the U.S. Lessons for public health from peanut allergy advice.
For decades, peanut allergies were on the rise in the US. But a study released on October 20 found that peanut allergies in babies and young children are now decreasing. This drop correlates with a change in guidance from the National Institute of Allergy and Infectious Diseases. In 2017, the agency started recommending exposing children to peanuts “early and often.” Since that recommendation, the prevalence of peanut allergies has dropped significantly.Sharon Chinthrajah, a physician specializing in allergies and immunology, churns through the findings with Host Flora Lichtman. Guest: Dr. Sharon Chinthrajah is a physician specializing in allergy and immunology at the Sean N. Parker Center at Stanford University.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.
Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest: Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices
Thousands of children may be avoiding peanut allergies thanks to research indicating that early exposure to—rather than avoidance of—the legume is key. Now there's reason to believe this is true for tons of allergens – and that the great “pandemic” of kid food allergies never needed to happen. Guest: Dr. David Hill, attending physician with the Division of Allergy and Immunology at Children's Hospital of Philadelphia, and The Hill Lab. Want more What Next? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and across all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen. Podcast production by Elena Schwartz, Paige Osburn, Anna Phillips, Madeline Ducharme, and Rob Gunther. Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2026 Ivy Podcast Discovery LLC
